Roxadustat vs Vadadustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

Roxadustat · Evrenzo

Marketed by Kyntra Bio and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT01750190 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in 922 non-dialysis CKD patients with anemia. The two primary efficacy endpoints—mean change in hemoglobin over weeks 28-52 and hemoglobin response during the first 24 weeks—were both statistically significant and strongly favored roxadustat over placebo (p<0.0001 for both). The study was adequately powered and used a hard hemoglobin-based clinical endpoint, supporting a strong design and result.

Next expected readout: October 2027 · NCT05970172 (registry estimate)

Reported efficacy

United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy (Baseline (Day 1, Week 0), Weeks 28 to 52); Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy (Baseline up to Week 24): Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001). (met)

Result source: NCT01750190

Vadadustat · Vafseo

Marketed by Akebia Therapeutics and partners

Approved in Chronic Kidney Diseasesmall molecule
Partial signal

NCT02648347 · Phase 3 · completed

Participants were randomized to vadadustat or active treatment with darbepoetin alfa, but the trial was open-label; 879 received vadadustat and 872 received darbepoetin alfa. The hemoglobin primary endpoint met the prespecified non-inferiority criterion, while the primary cardiovascular safety comparison did not, making the findings mixed rather than clearly positive.

Next expected readout: April 2027 · NCT07565701 (registry estimate)

Reported efficacy

Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36); Median Time to First Major Adverse Cardiovascular Event (MACE) (Up to Week 208): Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037) (mixed)

Result source: NCT02680574

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRoxadustatVadadustat
Kidney composite outcome—Trial running · NCT05970172—Not posted · NCT02892149
UACR, % change—Trial running · NCT05970172—Not posted · NCT02892149
eGFR slope-2.6 vs -3.2+0.6 vs placebon 389NCT01887600—Not posted · NCT02892149
Haemoglobin, change2 vs 0.2+1.8 vs placebowk 52 · n 616NCT01750190
169 other results
  • 1.8 vs 0.4 wk 52 · n 1334 · Phase 3 · primary NCT02174627
  • 2.0 vs 0.3 n 312 · Phase 3 · primary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 522 · Phase 3 · primary NCT02052310
  • 0.4 vs -0.1 wk 52 · n 370 · Phase 3 · primary NCT02273726
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · primary NCT02278341
  • 0.4 vs 0.2 wk 36 · n 354 · Phase 3 · primary NCT02278341
  • 0.8 vs 0.7 n 1003 · Phase 3 · primary NCT02174731
  • 0.5 vs -0.0 wk 36 · n 303 · Phase 3 · primary NCT02273726
  • 1.9 vs 0.3 wk 52 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.6 wk 52 · n 213 · Phase 3 · secondary NCT02174627
  • 2.0 vs 0.3 wk 44 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 40 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.2 wk 36 · n 608 · Phase 3 · secondary NCT01750190
  • 2.0 vs 0.2 wk 52 · n 156 · Phase 3 · secondary NCT01750190
  • 1.7 vs 0.2 wk 48 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 56 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 60 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.2 wk 64 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.4 wk 36 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.4 wk 68 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 32 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 72 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 28 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.7 wk 76 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 24 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 80 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 22 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.4 wk 20 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 84 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 18 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.4 wk 16 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.4 wk 88 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 14 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.3 wk 12 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 92 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 10 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 8 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 96 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.1 wk 6 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.1 wk 4 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 100 · n 389 · Phase 3 · secondary NCT01887600
  • 1.0 vs 0.0 wk 2 · n 389 · Phase 3 · secondary NCT01887600
  • 0.4 vs -0.0 wk 1 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 104 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.5 n 311 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 n 312 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 n 291 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 n 124 · Phase 3 · secondary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 490 · Phase 3 · secondary NCT02052310
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 48 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 56 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.3 wk 44 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 60 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 40 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs -0.1 wk 64 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 36 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 68 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.1 wk 34 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 32 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 72 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 30 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.3 wk 28 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 76 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 26 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 24 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 22 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 20 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.0 wk 18 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.2 wk 16 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.0 wk 14 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs 0.1 wk 12 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs -0.0 wk 10 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 8 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 7 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.1 wk 6 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 5 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 4 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.1 wk 3 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.7 n 836 · Phase 3 · secondary NCT02174731
  • 2.3 vs 2.5 wk 24 · n 228 · Phase 3 · secondary NCT02052310
  • 0.6 vs -0.0 wk 24 · n 189 · Phase 3 · secondary NCT02273726
  • 0.1 vs -0.0 wk 80 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 84 · n 413 · Phase 3 · secondary NCT02278341
  • 0.0 vs -0.0 wk 88 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 92 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.1 wk 96 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 100 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.1 wk 2 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 1 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 104 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.6 n 280 · Phase 3 · secondary NCT02174731
  • 2.7 vs 2.5 n 435 · Phase 3 · secondary NCT02052310
  • 1.2 vs 0.0 2.0 mg/kg BIW · wk 8 · n 9 · Phase 2 · primary NCT00761657
  • 1.5 vs 0.0 2.0 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.8 vs 0.0 1.5 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 1.3 vs 0.0 1.5 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.5 vs 0.0 1.0 mg/kg BIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.1 vs 0.0 1.0 mg/kg TIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.6 vs 0.0 0.7 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 0.2 vs 0.0 0.7 mg/kg TIW · wk 8 · n 12 · Phase 2 · primary NCT00761657
  • 0.7 vs -2.5 2.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -2.0 vs -2.4 2.0 mg/kg TIW · wk 12 · n 3 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.8 mg/kg TIW · wk 20 · n 6 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.8 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 19 · n 6 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.8 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 6 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 14 · n 6 · Phase 2 · secondary NCT01147666
  • -0.0 vs -2.4 1.8 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 1.8 mg/kg TIW · wk 12 · n 6 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.8 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • 0.6 vs -2.4 1.8 mg/kg TIW · wk 10 · n 6 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 1.8 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 8 · n 6 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 1.8 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • 0.9 vs -2.5 1.5 mg/kg TIW · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.3 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.3 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 1.3 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.3 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.5 1.3 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.5 Weight Tiered 70-100-150 mg · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.4 Weight Tiered 70-100-150 mg · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.4 Weight Tiered 70-100-150 mg · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • 0.4 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-100-150 mg · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.5 2.0 mg/kg · wk 20 · n 2 · Phase 2 · secondary NCT01147666
  • -2.8 vs -2.5 2.0 mg/kg TIW · wk 20 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 19 · n 2 · Phase 2 · secondary NCT01147666
  • -3.0 vs -2.4 2.0 mg/kg TIW · wk 19 · n 3 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 2.0 mg/kg · wk 17 · n 2 · Phase 2 · secondary NCT01147666
  • -2.7 vs -2.4 2.0 mg/kg TIW · wk 17 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 14 · n 2 · Phase 2 · secondary NCT01147666
  • -2.3 vs -2.4 2.0 mg/kg TIW · wk 14 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 12 · n 2 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 10 · n 2 · Phase 2 · secondary NCT01147666
  • -1.5 vs -2.4 2.0 mg/kg TIW · wk 10 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 8 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.4 2.0 mg/kg TIW · wk 8 · n 3 · Phase 2 · secondary NCT01147666
  • 0 vs -2.5 2.0 mg/kg · wk 7 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.5 2.0 mg/kg TIW · wk 7 · n 3 · Phase 2 · secondary NCT01147666
  • -2.6 vs -2.5 1.5 mg/kg TIW · wk 7 · n 1 · Phase 2 · secondary NCT01147666
1.4 vs 1.4vs Darbepoetin Alfan 879NCT02648347
34 other results
  • 0.4 vs 0.4 wk 52 · n 862 · Phase 3 · secondary NCT02680574
  • 1.5 vs 1.5 n 879 · Phase 3 · secondary NCT02648347
  • 0.2 vs 0.4 n 1777 · Phase 3 · secondary NCT02892149
  • 1.4 vs 1.5 wk 52 · n 181 · Phase 3 · secondary NCT02865850
  • 0.9 vs -0.1 wk 20 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.2 wk 19 · n 135 · Phase 2 · secondary NCT01906489
  • 0.8 vs -0.2 wk 16 · n 135 · Phase 2 · secondary NCT01906489
  • 0.9 vs -0.2 wk 12 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.4 wk 8 · n 135 · Phase 2 · secondary NCT01906489
  • 0.6 vs -0.4 wk 6 · n 135 · Phase 2 · secondary NCT01906489
  • 0.4 vs -0.3 wk 4 · n 135 · Phase 2 · secondary NCT01906489
  • 0.1 vs -0.2 wk 2 · n 135 · Phase 2 · secondary NCT01906489
  • 1.4 vs -0.0 630 mg · wk 6 · n 19 · Phase 2 · secondary NCT01381094
  • 1.1 vs 0.1 630 mg · wk 4 · n 19 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 630 mg · wk 2 · n 19 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 630 mg · wk 1 · n 19 · Phase 2 · secondary NCT01381094
  • 1.3 vs -0.0 500 mg · wk 6 · n 17 · Phase 2 · secondary NCT01381094
  • 0.8 vs 0.1 500 mg · wk 4 · n 17 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 500 mg · wk 2 · n 17 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 500 mg · wk 1 · n 17 · Phase 2 · secondary NCT01381094
  • 0.7 vs -0.0 370 mg · wk 6 · n 16 · Phase 2 · secondary NCT01381094
  • 0.4 vs 0.1 370 mg · wk 4 · n 16 · Phase 2 · secondary NCT01381094
  • 0 vs 0.1 370 mg · wk 2 · n 16 · Phase 2 · secondary NCT01381094
  • -0.1 vs 0.0 370 mg · wk 1 · n 16 · Phase 2 · secondary NCT01381094
  • 0.8 vs -0.0 240 mg · wk 6 · n 18 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 240 mg · wk 4 · n 18 · Phase 2 · secondary NCT01381094
  • 0.2 vs 0.1 240 mg · wk 2 · n 18 · Phase 2 · secondary NCT01381094
  • 0.1 vs 0.0 240 mg · wk 1 · n 18 · Phase 2 · secondary NCT01381094
  • -0.2 vs 0.1 300 mg · wk 20 · n 26 · Phase 2 · secondary NCT03799627
  • -0.2 vs 0.1 450 mg · wk 20 · n 24 · Phase 2 · secondary NCT03799627
  • 0.1 vs 0.1 300 mg · wk 20 · n 7 · Phase 2 · secondary NCT03799627
  • -0.5 vs 0.1 600 mg · wk 20 · n 10 · Phase 2 · secondary NCT03799627
  • -0.4 vs 0.1 450 mg · wk 20 · n 14 · Phase 2 · secondary NCT03799627
  • -0.3 vs 0.1 600 mg · wk 20 · n 3 · Phase 2 · secondary NCT03799627

Kidney composite outcome

Roxadustat
—Trial running · NCT05970172
Vadadustat
—Not posted · NCT02892149

UACR, % change

Roxadustat
—Trial running · NCT05970172
Vadadustat
—Not posted · NCT02892149

eGFR slope

Roxadustat
-2.6 vs -3.2+0.6 vs placebon 389NCT01887600
Vadadustat
—Not posted · NCT02892149

Haemoglobin, change

Roxadustat
2 vs 0.2+1.8 vs placebowk 52 · n 616NCT01750190
169 other results
  • 1.8 vs 0.4 wk 52 · n 1334 · Phase 3 · primary NCT02174627
  • 2.0 vs 0.3 n 312 · Phase 3 · primary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 522 · Phase 3 · primary NCT02052310
  • 0.4 vs -0.1 wk 52 · n 370 · Phase 3 · primary NCT02273726
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · primary NCT02278341
  • 0.4 vs 0.2 wk 36 · n 354 · Phase 3 · primary NCT02278341
  • 0.8 vs 0.7 n 1003 · Phase 3 · primary NCT02174731
  • 0.5 vs -0.0 wk 36 · n 303 · Phase 3 · primary NCT02273726
  • 1.9 vs 0.3 wk 52 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.6 wk 52 · n 213 · Phase 3 · secondary NCT02174627
  • 2.0 vs 0.3 wk 44 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 40 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.2 wk 36 · n 608 · Phase 3 · secondary NCT01750190
  • 2.0 vs 0.2 wk 52 · n 156 · Phase 3 · secondary NCT01750190
  • 1.7 vs 0.2 wk 48 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 56 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 60 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.2 wk 64 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.4 wk 36 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.4 wk 68 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 32 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 72 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 28 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.7 wk 76 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 24 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 80 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 22 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.4 wk 20 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 84 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 18 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.4 wk 16 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.4 wk 88 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 14 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.3 wk 12 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 92 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 10 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 8 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 96 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.1 wk 6 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.1 wk 4 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 100 · n 389 · Phase 3 · secondary NCT01887600
  • 1.0 vs 0.0 wk 2 · n 389 · Phase 3 · secondary NCT01887600
  • 0.4 vs -0.0 wk 1 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 104 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.5 n 311 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 n 312 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 n 291 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 n 124 · Phase 3 · secondary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 490 · Phase 3 · secondary NCT02052310
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 48 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 56 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.3 wk 44 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 60 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 40 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs -0.1 wk 64 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 36 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 68 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.1 wk 34 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 32 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 72 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 30 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.3 wk 28 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 76 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 26 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 24 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 22 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 20 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.0 wk 18 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.2 wk 16 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.0 wk 14 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs 0.1 wk 12 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs -0.0 wk 10 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 8 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 7 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.1 wk 6 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 5 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 4 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.1 wk 3 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.7 n 836 · Phase 3 · secondary NCT02174731
  • 2.3 vs 2.5 wk 24 · n 228 · Phase 3 · secondary NCT02052310
  • 0.6 vs -0.0 wk 24 · n 189 · Phase 3 · secondary NCT02273726
  • 0.1 vs -0.0 wk 80 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 84 · n 413 · Phase 3 · secondary NCT02278341
  • 0.0 vs -0.0 wk 88 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 92 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.1 wk 96 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 100 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.1 wk 2 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 1 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 104 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.6 n 280 · Phase 3 · secondary NCT02174731
  • 2.7 vs 2.5 n 435 · Phase 3 · secondary NCT02052310
  • 1.2 vs 0.0 2.0 mg/kg BIW · wk 8 · n 9 · Phase 2 · primary NCT00761657
  • 1.5 vs 0.0 2.0 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.8 vs 0.0 1.5 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 1.3 vs 0.0 1.5 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.5 vs 0.0 1.0 mg/kg BIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.1 vs 0.0 1.0 mg/kg TIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.6 vs 0.0 0.7 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 0.2 vs 0.0 0.7 mg/kg TIW · wk 8 · n 12 · Phase 2 · primary NCT00761657
  • 0.7 vs -2.5 2.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -2.0 vs -2.4 2.0 mg/kg TIW · wk 12 · n 3 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.8 mg/kg TIW · wk 20 · n 6 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.8 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 19 · n 6 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.8 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 6 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 14 · n 6 · Phase 2 · secondary NCT01147666
  • -0.0 vs -2.4 1.8 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 1.8 mg/kg TIW · wk 12 · n 6 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.8 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • 0.6 vs -2.4 1.8 mg/kg TIW · wk 10 · n 6 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 1.8 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 8 · n 6 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 1.8 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • 0.9 vs -2.5 1.5 mg/kg TIW · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.3 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.3 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 1.3 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.3 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.5 1.3 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.5 Weight Tiered 70-100-150 mg · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.4 Weight Tiered 70-100-150 mg · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.4 Weight Tiered 70-100-150 mg · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • 0.4 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-100-150 mg · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.5 2.0 mg/kg · wk 20 · n 2 · Phase 2 · secondary NCT01147666
  • -2.8 vs -2.5 2.0 mg/kg TIW · wk 20 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 19 · n 2 · Phase 2 · secondary NCT01147666
  • -3.0 vs -2.4 2.0 mg/kg TIW · wk 19 · n 3 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 2.0 mg/kg · wk 17 · n 2 · Phase 2 · secondary NCT01147666
  • -2.7 vs -2.4 2.0 mg/kg TIW · wk 17 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 14 · n 2 · Phase 2 · secondary NCT01147666
  • -2.3 vs -2.4 2.0 mg/kg TIW · wk 14 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 12 · n 2 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 10 · n 2 · Phase 2 · secondary NCT01147666
  • -1.5 vs -2.4 2.0 mg/kg TIW · wk 10 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 8 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.4 2.0 mg/kg TIW · wk 8 · n 3 · Phase 2 · secondary NCT01147666
  • 0 vs -2.5 2.0 mg/kg · wk 7 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.5 2.0 mg/kg TIW · wk 7 · n 3 · Phase 2 · secondary NCT01147666
  • -2.6 vs -2.5 1.5 mg/kg TIW · wk 7 · n 1 · Phase 2 · secondary NCT01147666
Vadadustat
1.4 vs 1.4vs Darbepoetin Alfan 879NCT02648347
34 other results
  • 0.4 vs 0.4 wk 52 · n 862 · Phase 3 · secondary NCT02680574
  • 1.5 vs 1.5 n 879 · Phase 3 · secondary NCT02648347
  • 0.2 vs 0.4 n 1777 · Phase 3 · secondary NCT02892149
  • 1.4 vs 1.5 wk 52 · n 181 · Phase 3 · secondary NCT02865850
  • 0.9 vs -0.1 wk 20 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.2 wk 19 · n 135 · Phase 2 · secondary NCT01906489
  • 0.8 vs -0.2 wk 16 · n 135 · Phase 2 · secondary NCT01906489
  • 0.9 vs -0.2 wk 12 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.4 wk 8 · n 135 · Phase 2 · secondary NCT01906489
  • 0.6 vs -0.4 wk 6 · n 135 · Phase 2 · secondary NCT01906489
  • 0.4 vs -0.3 wk 4 · n 135 · Phase 2 · secondary NCT01906489
  • 0.1 vs -0.2 wk 2 · n 135 · Phase 2 · secondary NCT01906489
  • 1.4 vs -0.0 630 mg · wk 6 · n 19 · Phase 2 · secondary NCT01381094
  • 1.1 vs 0.1 630 mg · wk 4 · n 19 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 630 mg · wk 2 · n 19 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 630 mg · wk 1 · n 19 · Phase 2 · secondary NCT01381094
  • 1.3 vs -0.0 500 mg · wk 6 · n 17 · Phase 2 · secondary NCT01381094
  • 0.8 vs 0.1 500 mg · wk 4 · n 17 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 500 mg · wk 2 · n 17 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 500 mg · wk 1 · n 17 · Phase 2 · secondary NCT01381094
  • 0.7 vs -0.0 370 mg · wk 6 · n 16 · Phase 2 · secondary NCT01381094
  • 0.4 vs 0.1 370 mg · wk 4 · n 16 · Phase 2 · secondary NCT01381094
  • 0 vs 0.1 370 mg · wk 2 · n 16 · Phase 2 · secondary NCT01381094
  • -0.1 vs 0.0 370 mg · wk 1 · n 16 · Phase 2 · secondary NCT01381094
  • 0.8 vs -0.0 240 mg · wk 6 · n 18 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 240 mg · wk 4 · n 18 · Phase 2 · secondary NCT01381094
  • 0.2 vs 0.1 240 mg · wk 2 · n 18 · Phase 2 · secondary NCT01381094
  • 0.1 vs 0.0 240 mg · wk 1 · n 18 · Phase 2 · secondary NCT01381094
  • -0.2 vs 0.1 300 mg · wk 20 · n 26 · Phase 2 · secondary NCT03799627
  • -0.2 vs 0.1 450 mg · wk 20 · n 24 · Phase 2 · secondary NCT03799627
  • 0.1 vs 0.1 300 mg · wk 20 · n 7 · Phase 2 · secondary NCT03799627
  • -0.5 vs 0.1 600 mg · wk 20 · n 10 · Phase 2 · secondary NCT03799627
  • -0.4 vs 0.1 450 mg · wk 20 · n 14 · Phase 2 · secondary NCT03799627
  • -0.3 vs 0.1 600 mg · wk 20 · n 3 · Phase 2 · secondary NCT03799627
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Roxadustat: 8 of 8 rows · Vadadustat: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRoxadustat
Rows use multiple source trials
Vadadustat
Rows use multiple source trials
Hemoglobin
responder rate · % of participants
84.2% (n=386) vs 82.4% (n=397) ESA @ 36wka,b,c,d,e
NCT02278341 · Phase 3 · registry result, not featured evidence
show 1 more dose
83.1% (n=413) vs 82.1% (n=420) ESA @ 36wk
NCT02278341 · Phase 3 · registry result, not featured evidence
42.9% (n=7) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mga,b,c,d,e
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
show 5 more doses
38.5% (n=26) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
33.3% (n=3) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
20% (n=10) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
35.7% (n=14) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
45.8% (n=24) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
Hemoglobin Change g/dL
absolute change · g/dL
No placebo or comparator arm
0.46 g/dLb,c,d,f
NCT04410198 · Phase 3 · registry result, not featured evidence
6 other source trials
2.42 g/dL @ 16wkTiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
2.32 g/dL @ 16wkTiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
1.85 g/dL @ 16wk50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
2.21 g/dL @ 16wk100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
1.37 g/dL @ 16wkTiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
1.42 g/dL @ 16wk70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
-0.03 g/dL @ 16wk300 mg Once Daily (QD)a,b,c,d,f
NCT02260193 · Phase 2 · registry result, not featured evidence
show 2 more doses
-0.06 g/dL @ 16wk450 mg 3 Times Per Week (TIW)
NCT02260193 · Phase 2 · registry result, not featured evidence
-0.13 g/dL @ 16wk450 mg QD
NCT02260193 · Phase 2 · registry result, not featured evidence
Hemoglobin Level g/dL
absolute value · g/dL
11.106 vs 9.468 placebo g/dLa,b,c,d,f
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more doses
10.984 vs 9.381 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
10.816 vs 9.324 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
10.88 vs 9.93 placebo g/dL @ 20wkb,c,d,f
NCT01906489 · Phase 2 · registry result, not featured evidence
Time to Hgb Target
time to event · months
No placebo or comparator arm
2.21 months*b,c,d,f
NCT03461146 · Phase 3 · registry result, not featured evidence · converted to months from 67.2 days as posted
6 other source trials
0.92 months*Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted
0.92 months*Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted
1.61 months*50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 48.9 days as posted
0.92 months*100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted
1.15 months*Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 35 days as posted
1.84 months*70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence · converted to months from 56 days as posted
1.87 months @ 16wk*300 mga,b,c,d,f
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 57 days as posted
show 4 more doses
2.6 months @ 16wk*300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 79.2 days as posted
2.79 months @ 16wk*600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 85 days as posted
1.79 months @ 16wk*600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 54.6 days as posted
2.28 months @ 16wk*150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 69.3 days as posted
Dropout rate
43.3%g
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
22.6%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
37.3%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
7.7%
NCT04655027 · Phase 4 · registry result, not featured evidence
18.2%
NCT04410198 · Phase 3 · registry result, not featured evidence
26.5%
NCT03329196 · Phase 3 · registry result, not featured evidence
25.9%
NCT03439137 · Phase 3 · registry result, not featured evidence
14.3%
NCT03402386 · Phase 3 · registry result, not featured evidence
12.5%
NCT03461146 · Phase 3 · registry result, not featured evidence
6.1%
NCT02174627 · Phase 3 · registry result, not featured evidence
6.6%
NCT02174731 · Phase 3 · registry result, not featured evidence
41.2%
NCT02052310 · Phase 3 · registry result, not featured evidence
65.7%
NCT02273726 · Phase 3 · registry result, not featured evidence
28.4%
NCT02278341 · Phase 3 · registry result, not featured evidence
66.7%
NCT01630889 · Phase 2 · registry result, not featured evidence
8.3%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
80%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
50%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
20%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
4.2%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
16%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
8.3%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
100%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
50%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
33.3%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
60%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
23.8%h
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 46 more results
18.3%
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
11.6%
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
19.8%
NCT02892149 · Phase 3
35.5%900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
34.9%600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
55.6%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
22.9%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
40%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
61.9%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
42.9%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
32.4%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
80%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
13.3%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
60%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
13.3%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
40%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
26.7%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
20%300 mg Once Daily (QD)
NCT02260193 · Phase 2 · registry result, not featured evidence
32.3%450 mg 3 Times Per Week (TIW)
NCT02260193 · Phase 2 · registry result, not featured evidence
27.3%450 mg QD
NCT02260193 · Phase 2 · registry result, not featured evidence
18.8%
NCT01906489 · Phase 2 · registry result, not featured evidence
5.3%630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
16.7%370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
11.1%240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%
NCT01235936 · Phase 2 · registry result, not featured evidence
0%Cohort 1: CKD Stage 3 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
0%Cohort 2: CKD Stage 4 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
7.6%g
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
0.6%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
5.4%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT04655027 · Phase 4 · registry result, not featured evidence
2%
NCT04410198 · Phase 3 · registry result, not featured evidence
6.6%
NCT03329196 · Phase 3 · registry result, not featured evidence
9.9%
NCT03439137 · Phase 3 · registry result, not featured evidence
7.1%
NCT03402386 · Phase 3 · registry result, not featured evidence
8.3%
NCT03461146 · Phase 3 · registry result, not featured evidence
—
NCT02174627 · Phase 3 · registry result, not featured evidence
—
NCT02174731 · Phase 3 · registry result, not featured evidence
5.6%
NCT02052310 · Phase 3 · registry result, not featured evidence
7.3%
NCT02273726 · Phase 3 · registry result, not featured evidence
0.7%
NCT02278341 · Phase 3 · registry result, not featured evidence
—
NCT01630889 · Phase 2 · registry result, not featured evidence
8.3%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
20%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
8.3%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
8.3%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
4%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
4.2%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
10%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—h
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 46 more results
—
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT02892149 · Phase 3
11.8%900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
5.9%600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
2.9%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
40%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
23.8%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
9.5%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
5.9%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
10%300 mg Once Daily (QD)
NCT02260193 · Phase 2 · registry result, not featured evidence
3.2%450 mg 3 Times Per Week (TIW)
NCT02260193 · Phase 2 · registry result, not featured evidence
12.1%450 mg QD
NCT02260193 · Phase 2 · registry result, not featured evidence
7.2%
NCT01906489 · Phase 2 · registry result, not featured evidence
5.3%630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
11.1%370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
5.6%240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
—
NCT01235936 · Phase 2 · registry result, not featured evidence
—Cohort 1: CKD Stage 3 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
—Cohort 2: CKD Stage 4 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
Serious AEs
52.5%g
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
64.7%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
61.6%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0%
NCT04655027 · Phase 4 · registry result, not featured evidence
25.6%
NCT04410198 · Phase 3 · registry result, not featured evidence
27.8%
NCT03329196 · Phase 3 · registry result, not featured evidence
25.3%
NCT03439137 · Phase 3 · registry result, not featured evidence
28.6%
NCT03402386 · Phase 3 · registry result, not featured evidence
29.2%
NCT03461146 · Phase 3 · registry result, not featured evidence
57.4%
NCT02174627 · Phase 3 · registry result, not featured evidence
57.6%
NCT02174731 · Phase 3 · registry result, not featured evidence
44.8%
NCT02052310 · Phase 3 · registry result, not featured evidence
65.4%
NCT02273726 · Phase 3 · registry result, not featured evidence
50.7%
NCT02278341 · Phase 3 · registry result, not featured evidence
60%
NCT01630889 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
40%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
33.3%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
50%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
30%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
40%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
16.7%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
16.7%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
41.7%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
30.8%0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
65.3%h
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 46 more results
58.5%
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
49.7%
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
55%
NCT02892149 · Phase 3
44%900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
45%600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
44.4%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
26.5%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
80%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
47.6%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
28.6%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
20%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
6.7%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
6.7%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
20%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
6.7%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
41.7%300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
15.4%600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
16.7%300 mg Once Daily (QD)
NCT02260193 · Phase 2 · registry result, not featured evidence
25.8%450 mg 3 Times Per Week (TIW)
NCT02260193 · Phase 2 · registry result, not featured evidence
27.3%450 mg QD
NCT02260193 · Phase 2 · registry result, not featured evidence
23.9%
NCT01906489 · Phase 2 · registry result, not featured evidence
5.3%630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
5.9%500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
16.7%370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
11.1%240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%
NCT01235936 · Phase 2 · registry result, not featured evidence
0%Cohort 1: CKD Stage 3 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
0%Cohort 2: CKD Stage 4 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
g
constipation 16.9% (placebo 11.1%)
hyperkalemia 16% (placebo 12.5%)
viral upper respiratory tract infection 15.9% (placebo 13.1%)
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
hypertension 28.8%
oedema peripheral 14.9%
nausea 10.8%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
hypertension 21.7% (placebo 13.3%)
oedema peripheral 11.3% (placebo 10.3%)
viral upper respiratory tract infection 9.7% (placebo 4.4%)
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
abdominal infection 7.7%
back pain 7.7%
hyperkalaemia 7.7%
NCT04655027 · Phase 4 · registry result, not featured evidence
diarrhoea 7.4%
cough 5.9%
covid-19 5.4%
NCT04410198 · Phase 3 · registry result, not featured evidence
nasopharyngitis 24.5%
diarrhoea 11.9%
constipation 9.3%
NCT03329196 · Phase 3 · registry result, not featured evidence
nasopharyngitis 45.7%
diarrhoea 15.4%
contusion 13%
NCT03439137 · Phase 3 · registry result, not featured evidence
catheter site infection 21.4%
diarrhoea 19%
nasopharyngitis 14.3%
NCT03402386 · Phase 3 · registry result, not featured evidence
nasopharyngitis 20.8%
shunt stenosis 20.8%
diarrhoea 16.7%
NCT03461146 · Phase 3 · registry result, not featured evidence
urinary tract infection 11% (placebo 6.8%)
hypertension 10.7% (placebo 8.5%)
oedema peripheral 10.4% (placebo 7.7%)
NCT02174627 · Phase 3 · registry result, not featured evidence
diarrhoea 10.9%
hypertension 8.1%
headache 7.5%
NCT02174731 · Phase 3 · registry result, not featured evidence
hypertension 18.4%
diarrhea 13.8%
muscle spasms 11.5%
NCT02052310 · Phase 3 · registry result, not featured evidence
nausea 17%
vomiting 16.2%
hypertension 15.9%
NCT02273726 · Phase 3 · registry result, not featured evidence
hypertension 15.9%
headache 8.7%
diarrhoea 8%
NCT02278341 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 40%
cough 33.3%
abdominal pain 20%
NCT01630889 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
nausea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
2.0 mg/kg
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
catheter site pain 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
cough 20% (placebo 0%)
fatigue 20% (placebo 0%)
haemoglobin decreased 20% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.8 mg/kg TIW
anaemia 16.7% (placebo 25%)
diarrhoea 16.7% (placebo 0%)
nausea 8.3% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.8 mg/kg TIW
diarrhoea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
diarrhoea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
anaemia 25% (placebo 25%)
arteriovenous fistula site complication 25% (placebo 0%)
catheter site pain 25% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.3 mg/kg TIW
diarrhoea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.0 mg/kg TIW
nausea 25% (placebo 0%)
diarrhoea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-120-200 mg
anaemia 20% (placebo 25%)
nausea 10% (placebo 0%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-100-150 mg
anaemia 8.3% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
catheter site pain 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-120-200 mg
nausea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
100 mg TIW
nausea 12.5%
diarrhoea 8.3%
headache 8.3%
NCT01244763 · Phase 2 · registry result, not featured evidence
70 mg BIW Then QW
oedema peripheral 16%
urinary tract infection 12%
nasopharyngitis 8%
NCT01244763 · Phase 2 · registry result, not featured evidence
50 mg TIW
oedema peripheral 16.7%
dizziness 12.5%
diarrhoea 8.3%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing TIW
hypertension 16.7%
nausea 16.7%
diarrhoea 12.5%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing TIW Then BIW
oedema peripheral 20.8%
diarrhoea 16.7%
urinary tract infection 16.7%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing BIW Then QW
nausea 20.8%
urinary tract infection 16.7%
constipation 12.5%
NCT01244763 · Phase 2 · registry result, not featured evidence
2.0 mg/kg BIW
fatigue 18.2% (placebo 0%)
back pain 9.1% (placebo 3.6%)
diarrhoea 9.1% (placebo 7.1%)
NCT00761657 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
allergic sinusitis 8.3% (placebo 0%)
benign breast neoplasm 8.3% (placebo 0%)
cystitis 8.3% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.5 mg/kg BIW
headache 30% (placebo 3.6%)
hyperkalaemia 20% (placebo 0%)
back pain 10% (placebo 3.6%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
hyperuricaemia 18.2% (placebo 0%)
renal impairment 18.2% (placebo 0%)
acidosis 9.1% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.0 mg/kg BIW
diarrhoea 16.7% (placebo 7.1%)
anorexia 8.3% (placebo 0%)
chills 8.3% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.0 mg/kg TIW
back pain 22.2% (placebo 3.6%)
prostatitis 16.7% (placebo 0%)
breast cyst 11.1% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
0.7 mg/kg BIW
anaemia 10% (placebo 0%)
hyperkalaemia 10% (placebo 0%)
hypernatraemia 10% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
0.7 mg/kg TIW
diarrhoea 23.1% (placebo 7.1%)
abdominal pain 7.7% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
h
hypertension 17.2%
diarrhoea 13%
oedema peripheral 12.5%
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 37 more results
hypertension 13.9%
diarrhoea 13.6%
urinary tract infection 10.8%
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
hypertension 15.1%
diarrhoea 10.1%
nausea 7.8%
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
diarrhoea 12.8%
hypertension 9.9%
headache 9%
NCT02892149 · Phase 3
900 mg TIW
diarrhoea 14%
covid 19 12%
hyperkalaemia 8.7%
NCT04707768 · Phase 3 · registry result, not featured evidence
600 mg TIW
covid 19 12.6%
diarrhoea 10.6%
nausea 7.9%
NCT04707768 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 22.2%
fall 11.1%
hyperkalaemia 11.1%
NCT03799627 · Phase 2 · registry result, not featured evidence
300 mg
cough 5.9%
headache 5.9%
influenza 5.9%
NCT03799627 · Phase 2 · registry result, not featured evidence
600 mg
acarodermatitis 20%
anaemia 20%
back pain 20%
NCT03799627 · Phase 2 · registry result, not featured evidence
600 mg
diarrhoea 19%
headache 14.3%
hypertension 14.3%
NCT03799627 · Phase 2 · registry result, not featured evidence
450 mg
arteriovenous fistula thrombosis 9.5%
diarrhoea 9.5%
fall 4.8%
NCT03799627 · Phase 2 · registry result, not featured evidence
450 mg
diarrhoea 8.6%
hypertension 8.6%
nasopharyngitis 8.6%
NCT03799627 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 13.3% (placebo 0%)
asthma 6.7% (placebo 0%)
cholelithiasis 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
300 mg
blood uric acid decreased 20% (placebo 0%)
nasopharyngitis 20% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 33.3% (placebo 0%)
diarrhoea 13.3% (placebo 20%)
blood parathyroid hormone increased 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
600 mg
anaemia macrocytic 6.7% (placebo 0%)
cardiac failure chronic 6.7% (placebo 0%)
dermal cyst 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
600 mg
catheter site erosion 20% (placebo 0%)
conjunctivitis 20% (placebo 0%)
diarrhoea 20% (placebo 20%)
NCT03054350 · Phase 2 · registry result, not featured evidence
600 mg
diarrhoea 13.3% (placebo 20%)
abdominal pain 6.7% (placebo 0%)
contusion 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 26.7% (placebo 0%)
contusion 13.3% (placebo 0%)
headache 13.3% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
150 mg
diarrhoea 20% (placebo 20%)
headache 20% (placebo 0%)
pneumonia 20% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
150 mg
arthralgia 6.7% (placebo 20%)
constipation 6.7% (placebo 0%)
cough 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
300 mg
constipation 16.7% (placebo 0%)
abdominal distension 8.3% (placebo 0%)
abdominal pain 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
300 mg
hypertension 25% (placebo 0%)
nausea 16.7% (placebo 0%)
angular cheilitis 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
600 mg
benign prostatic hyperplasia 7.7% (placebo 0%)
delirium 7.7% (placebo 0%)
diarrhoea 7.7% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
600 mg
hypertension 15.4% (placebo 0%)
aspartate aminotransferase increased 7.7% (placebo 0%)
back pain 7.7% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
150 mg
contusion 16.7% (placebo 0%)
abdominal distension 8.3% (placebo 0%)
back pain 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
150 mg
influenza 8.3% (placebo 0%)
oedema due to renal disease 8.3% (placebo 0%)
orthostatic hypotension 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
300 mg Once Daily (QD)
diarrhoea 13.3%
nausea 13.3%
arteriovenous fistula site complication 10%
NCT02260193 · Phase 2 · registry result, not featured evidence
450 mg 3 Times Per Week (TIW)
nausea 12.9%
back pain 9.7%
headache 9.7%
NCT02260193 · Phase 2 · registry result, not featured evidence
450 mg QD
abdominal pain 12.1%
diarrhoea 12.1%
dizziness 9.1%
NCT02260193 · Phase 2 · registry result, not featured evidence
diarrhoea 10.1% (placebo 4.2%)
nausea 10.1% (placebo 4.2%)
fatigue 8% (placebo 6.9%)
NCT01906489 · Phase 2 · registry result, not featured evidence
630 mg
hypertension 10.5% (placebo 15.8%)
abdominal pain 5.3% (placebo 0%)
adverse drug reaction 5.3% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
500 mg
hyperkalaemia 17.6% (placebo 5.3%)
nausea 11.8% (placebo 10.5%)
blood bicarbonate decreased 5.9% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
370 mg
abdominal discomfort 5.6% (placebo 0%)
abdominal pain upper 5.6% (placebo 0%)
blood uric acid increased 5.6% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
240 mg
headache 11.1% (placebo 0%)
urinary tract infection 11.1% (placebo 0%)
constipation 5.6% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
diarrhoea 20%
chills 10%
constipation 10%
NCT01235936 · Phase 2 · registry result, not featured evidence
nausea 20%
cold sweat 10%
headache 10%
NCT04707573 · Phase 2 · registry result, not featured evidence
back pain 8.3%
catheter site inflammation 8.3%
oropharyngeal pain 8.3%
NCT04707573 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 36 weeks versus 20 weeks.
  6. fThe assessment timepoint is not available for both results.
  7. gPopulation comparability has not been reviewed for 38 of these studies.
  8. hPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Roxadustat

Hemoglobin Ge 10 76.8% (n=608) vs 18.4% (n=305) placebo @ 36wk
event count · % of participants
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to % from 467 Participants as posted
LDL-C -18.48 vs 0.22 placebo mg/dL @ 28wk
absolute change · mg/dL
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
-23.8 vs -5.39 Epoetin Alfa mg/dL @ 24wk
NCT02052310 · Phase 3 · registry result, not featured evidence
-13.7 vs 1.23 Epoetin Alfa mg/dL @ 28wk
NCT02273726 · Phase 3 · registry result, not featured evidence
eGFR Slope -2.89 vs -3.1 placebo mL @ 52wk
absolute change · mL
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Hb 100% (n=9) vs 26.1% (n=23) placebo @ 8wk2.0 mg/kg BIW
responder rate · % of participants
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
show 18 more results
100% (n=11) vs 26.1% (n=23) placebo @ 8wk*2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
100% (n=9) vs 34.8% (n=23) placebo @ 16wk*2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
100% (n=11) vs 34.8% (n=23) placebo @ 16wk*2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
80% (n=10) vs 26.1% (n=23) placebo @ 8wk*1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
90.9% (n=11) vs 26.1% (n=23) placebo @ 8wk*1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
90% (n=10) vs 34.8% (n=23) placebo @ 16wk*1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
90.9% (n=11) vs 34.8% (n=23) placebo @ 16wk*1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
60% (n=5) vs 26.1% (n=23) placebo @ 8wk*1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
40% (n=5) vs 26.1% (n=23) placebo @ 8wk*1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
60% (n=5) vs 34.8% (n=23) placebo @ 16wk*1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
40% (n=5) vs 34.8% (n=23) placebo @ 16wk*1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
50% (n=10) vs 26.1% (n=23) placebo @ 8wk*0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
58.3% (n=12) vs 26.1% (n=23) placebo @ 8wk*0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
70% (n=10) vs 34.8% (n=23) placebo @ 16wk*0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
58.3% (n=12) vs 34.8% (n=23) placebo @ 16wk*0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
89.5% (n=286) vs 78% (n=273) Darbepoetin Alfa @ 24wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
77% (n=1371) vs 8.5% (n=1357) placebo @ 24wk
NCT02174627 · Phase 3 · registry result, not featured evidence
66.1% (n=369) vs 58.6% (n=370) Epoetin Alfa @ 52wk
NCT02273726 · Phase 3 · registry result, not featured evidence
Hb Change 1.848 vs 1.839 Darbepoetin Alfa g/dL @ 36wk
absolute change · g/dL
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 1 more result
1.718 vs 1.673 Darbepoetin Alfa g/dL @ 52wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
LDL-C -0.352 vs 0.049 Darbepoetin Alfa mmol/L @ 28wk
absolute change · mmol/L
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 3 more results
-0.38 vs -0.02 placebo mmol/L @ 24wk
NCT02174627 · Phase 3 · registry result, not featured evidence
-0.38 vs -0.05 Epoetin Alfa mmol/L @ 24wk
NCT02174731 · Phase 3 · registry result, not featured evidence
-0.459 vs -0.082 ESA mmol/L @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning 0.913 vs 2.062 Darbepoetin Alfa score @ 28wk
absolute change · score
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 3 more results
1.344 vs 0.632 placebo score
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0.14 vs -0.39 placebo score @ 28wk
NCT02174627 · Phase 3 · registry result, not featured evidence
0.05 vs -0.155 ESA score @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Time to Response 88.8% (n=322) vs 77.7% (n=292) Darbepoetin Alfa @ 24wk
responder rate · % of participants
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 1 more result
88.2% (n=322) vs 77.4% (n=292) Darbepoetin Alfa @ 24wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
SF-36 Vitality 2.788 vs 1.661 placebo score
absolute change · score
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
1.59 vs 1.15 placebo score @ 28wk
NCT02174627 · Phase 3 · registry result, not featured evidence
0.46 vs -0.396 ESA score @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Arterial Pressure -0.814 vs -1.656 placebo mmHg
absolute change · mmHg
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
-0.12 vs 1.15 Epoetin Alfa mmHg @ 12wk
NCT02052310 · Phase 3 · registry result, not featured evidence
0.46 vs 0.04 Epoetin Alfa mmHg @ 28wk
NCT02273726 · Phase 3 · registry result, not featured evidence
eGFR Slope Annualized -2.65 vs -3.24 placebo per year
event rate · per year
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Time to Hemoglobin Response 26% (n=389) vs 3.5% (n=203) placebo @ 4wk
responder rate · % of participants
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 3 more results
59.8% (n=389) vs 6.2% (n=203) placebo @ 8wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
83.4% (n=389) vs 9.4% (n=203) placebo @ 16wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
89.1% (n=389) vs 11.6% (n=203) placebo @ 24wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3

+ 57 further endpoints in the CSV export.

Vadadustat

Time to First MACE 10.55 vs 10.78 Darbepoetin Alfa months
time to event · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 45.71 weeks as posted
show 2 more results
6.05 vs 10.76 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 26.21 weeks as posted
11.28 vs 11.08 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 48.86 weeks as posted
MACE Plus HF Hosp Thromboembolic 8.69 vs 9.56 Darbepoetin Alfa months
absolute value · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 37.64 weeks as posted
show 3 more results
11.14 vs 11.37 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 48.29 weeks as posted
6.26 vs 10.85 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 27.14 weeks as posted
9.99 vs 10.43 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 43.29 weeks as posted
MACE 10.58 vs 9.66 Darbepoetin Alfa months
absolute value · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 45.86 weeks as posted
show 4 more results
12.28 vs 13.38 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 53.21 weeks as posted
10.52 vs 11.61 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 45.57 weeks as posted
4.27 vs 12.48 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 18.5 weeks as posted
10.29 vs 10.05 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 44.57 weeks as posted
CV Death 11.14 vs 9.66 Darbepoetin Alfa months
absolute value · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 48.29 weeks as posted
show 3 more results
11.14 vs 12.51 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 48.29 weeks as posted
5.08 vs 13.42 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 22 weeks as posted
10.65 vs 10.99 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 46.14 weeks as posted
Overall Survival 10.75 vs 11.03 Darbepoetin Alfa months
time to event · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 46.57 weeks as posted
show 3 more results
13.32 vs 14.34 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 57.71 weeks as posted
7.32 vs 10.47 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 31.71 weeks as posted
11.72 vs 11.64 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 50.79 weeks as posted
Hemoglobin Change g/dL 0.08 vs -1.48 placebo g @ 6wk300 mg
absolute change · g
NCT03054350 · Phase 2 · registry result, not featured evidence
show 16 more results
1.13 vs -0.47 placebo g @ 6wk300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0.14 vs 0.36 Mircera® g900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
-0.22 vs 0.16 Mircera® g900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
-0.07 vs 0.36 Mircera® g600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
-0.11 vs 0.16 Mircera® g600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
0.41 vs -1.48 placebo g @ 6wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
1.62 vs -0.47 placebo g @ 6wk600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
1.43 vs -0.03 placebo g @ 6wk630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
1.25 vs -0.03 placebo g @ 6wk500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0.73 vs -0.03 placebo g @ 6wk370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0.77 vs -0.03 placebo g @ 6wk240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
-0.28 vs -1.48 placebo g @ 6wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0.43 vs -0.47 placebo g @ 6wk150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0.41 vs 0.42 Darbepoetin Alfa g @ 36wk
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.26 vs 1.58 Darbepoetin Alfa g @ 36wk
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0.19 vs 0.36 Darbepoetin Alfa g
NCT02892149 · Phase 3
Hemoglobin Change g/dL -0.371 vs 0.16 Epoetin Alfa g @ 12wk300 mg
absolute change · g
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
show 5 more results
-0.911 vs 0.16 Epoetin Alfa g @ 12wk300 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
-0.418 vs 0.16 Epoetin Alfa g @ 12wk600 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
-0.671 vs 0.16 Epoetin Alfa g @ 12wk600 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
0.072 vs 0.16 Epoetin Alfa g @ 12wk450 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
-0.284 vs 0.16 Epoetin Alfa g @ 12wk450 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
Hemoglobin in Target Range 40% (n=30) vs 65.2% (n=23) Epoetin Alfa @ 12wk300 mg
event count · % of participants
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 12 Participants as posted
show 11 more results
8.3% (n=12) vs 65.2% (n=23) Epoetin Alfa @ 12wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
23.1% (n=26) vs 39.1% (n=23) Epoetin Alfa @ 20wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
28.6% (n=7) vs 39.1% (n=23) Epoetin Alfa @ 20wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=14) vs 65.2% (n=23) Epoetin Alfa @ 12wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
0% (n=4) vs 65.2% (n=23) Epoetin Alfa @ 12wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
20% (n=10) vs 39.1% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
33.3% (n=3) vs 39.1% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
43.3% (n=30) vs 65.2% (n=23) Epoetin Alfa @ 12wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
22.2% (n=18) vs 65.2% (n=23) Epoetin Alfa @ 12wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
29.2% (n=24) vs 39.1% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
21.4% (n=14) vs 39.1% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Hemoglobin in Target Range 0% (n=1) @ 20wk300 mg
event count · % of participants
No placebo or comparator arm
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
28.6% (n=7) @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
60% (n=5) @ 20wk*750 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
50% (n=4) @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
Hemoglobin Level g/dL 11.285 g/dL @ 16wk300 mg
absolute value · g/dL
Maintenance
No placebo or comparator arm
NCT03054350 · Phase 2 · registry result, not featured evidence
show 5 more results
13.2 g/dL @ 16wk300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
11.1 g/dL @ 16wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
12.1 g/dL @ 16wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
10.46 g/dL @ 16wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
8.6 g/dL @ 16wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
Hgb Target Range 10 12 84.6% (n=13) @ 16wk300 mg
event count · % of participants
Maintenance
No placebo or comparator arm
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
show 8 more results
0% (n=1) @ 16wk*300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
80% (n=10) @ 16wk*300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
58.3% (n=12) @ 16wk*600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
50% (n=2) @ 16wk*600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
91.7% (n=12) @ 16wk*600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
70% (n=10) @ 16wk*150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
0% (n=2) @ 16wk*150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
100% (n=11) @ 16wk*150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
Hemoglobin Change g/dL 2.444 g/dL @ 16wk300 mg
absolute change · g/dL
Maintenance
No placebo or comparator arm
NCT03054350 · Phase 2 · registry result, not featured evidence
show 8 more results
3.8 g/dL @ 16wk300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
1.61 g/dL @ 16wk300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
1.644 g/dL @ 16wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
3 g/dL @ 16wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
1.779 g/dL @ 16wk600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
1.397 g/dL @ 16wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
-0.233 g/dL @ 16wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0.982 g/dL @ 16wk150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence

+ 23 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Roxadustat's landscape · Vadadustat's landscape